Drug Trial Radar · NCT05166109
A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Jul 7, 2022
Primary completion
Aug 18, 2025
Study completion Aug 18, 2025
Sponsor
- Lead sponsor
- ReveraGen BioPharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Santhera Pharmaceuticals
- First posted
- Dec 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, PD, and exploratory clinical efficacy of vamorolone 500mg (250mg for body weight \<50 kg) daily administered orally compared to placebo over a treatment period of 24 weeks in males with BMD. Funding Source - FDA OOPD
Conditions
- Becker Muscular Dystrophy
Interventions
VamoroloneDrug
Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
PlaceboDrug
Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0Time frame: 24 weeks
- Total Number of Adverse Events as Assessed by CTCAE Version 5.0Time frame: 24 weeks
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
University of Pittsburgh
Pittsburgh, Pennsylvania
Azienda Ospedale Universita Padova
Padova, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.